Saturday 17 October 2026
Export TELO’s income statement to Excel — free account
Telomir Pharmaceuticals, Inc.
TELO Healthcare Biotechnology
In the quarter to June 2026, EPS fell 364.7% and free cash flow fell 45.3%, each against the same quarter a year earlier.
1.05
0.00
0.00%
Follow TELO
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 3.11 | 1.12 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 20.72 | 5.40 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 6 | 9 | 6 | 2 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | (1) | (13) | (17) | (10) | |||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | (1) | (13) | (17) | (10) | |||||
| Depreciation | — | — | — | — | — | — | — | 2 | 4 | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | (0.03) | (0.48) | (0.56) | (0.33) | |||||
| Cash flow | — | — | — | — | — | — | (0.02) | (0.14) | (0.17) | (0.12) | |||||
| Capex | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | — | — | (0.02) | (0.14) | (0.17) | (0.12) | |||||
| Book value | — | — | — | — | — | — | (0.03) | 0.13 | 0.02 | 0.19 | |||||
| Shares, m | — | — | — | — | — | — | 27 | 27 | 30 | 32 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | 0 | (4) | (5) | (4) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | — | — | 0 | (4) | (5) | (4) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | (1) | (1) | 1 | 6 | ||||
| Total debt | — | — | — | — | — | — | — | 0 | — | — | |||||
| Net debt | — | — | — | — | — | — | 0 | 0 | (1) | (7) | |||||
| Shareholders’ equity | — | — | — | — | — | — | (1) | 3 | 1 | 6 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (542.12) | (542.25) | (240.34) | ||||
| ROIC | — | — | — | — | — | — | 0.00 | (69.64) | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | 0.00 | (1,045.38) | (810.19) | (317.65) | |||||
Negative figures in brackets.
Charts ten years each
Telomir Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NMRA Neumora Therapeutics, Inc. | $80.2M | — (loss-making) | — | — | n/m | +24.45% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CLLS Cellectis S.A. | $79.9M | — (loss-making) | — | −62.05% (below 0%: shrinking) | n/m | −36.95% (below 0%: shrinking) | 100.00% | (340.69%) | Compare |
| PMN Promis Neurosciences | $78.0M | — (loss-making) | — | 0.00% | n/m | −169.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PTHS Pelthos Therapeutics Inc. | $77.6M | — (loss-making) | — (loss-making) | — | n/m | −1,614.99% (below 0%: shrinking) | 76.86% | (111.02%) | Compare |
| TELO Telomir Pharmaceuticals, Inc. | $77.3M | — (loss-making) | — | — | n/m | −45.34% (below 0%: shrinking) | — | 0.00% | |
| NTRB Nutriband Inc. | $76.2M | — (loss-making) | 4.6× | −29.72% (below 0%: shrinking) | n/m | +55.46% (above 0%: growing) | 41.58% | (203.57%) | Compare |
| CRDF Cardiff Oncology, Inc. | $75.5M | — (loss-making) | — (loss-making) | −14.05% (below 0%: shrinking) | n/m | −41.36% (below 0%: shrinking) | 100.00% | (9,245.19%) | Compare |
| ACRV Acrivon Therapeutics, Inc. | $75.4M | — (loss-making) | — | — | n/m | +12.59% (above 0%: growing) | 0.00% | 0.00% | Compare |
| OKYO OKYO Pharma Limited Sponsored ADR | $75.1M | — (loss-making) | — | — | n/m | +37.39% (above 0%: growing) | 0.00% | — | Compare |
| Median of peers | $76.9M | — | — | −21.89% | — | −12.18% | 20.79% | (111.02%) |
Telomir Pharmaceuticals, Inc. (TELO) key facts
- Telomir Pharmaceuticals, Inc. (TELO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, TELO traded at $1.05, a market capitalization of $77.3 million.
- Return on equity was −317.7% and debt-to-equity 0.03.